Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Beta2-mimetics such as Salbutamol have been shown to have ergogenic effects. Acute and chronic inhaled or oral doses of Salbutamol have been shown to increase whole body exercise and muscle performances. The underlying mechanisms are however unclear. Some data suggest that Salbutamol may have some effects on the central nervous system which may explain the improved exercise and neuromuscular performances. The present study aims to assess the effects of acite inhaled or oral Salbutamol intake on the neuromuscular system by using neurostimulation techniques and magnetic resonance imaging.
The effects of Salbutamol intake will be assessed by using transcranial magnetic stimulation on one hand and magnetic resonance imaging on the other hand. Maximal voluntary activation and cerebral activation will be measured during motor tasks performed until exhaustion after acute inhaled slabutamol intake, acture oral salbutamol intake or oral placebo intake.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Inhaled Salbutamol | Experimental | Acute inhalation of 800 microgram Salbutamol |
|
| Oral Salbutamol | Experimental | Acute oral intake of 4 mg Salbutamol |
|
| Placebo | Placebo Comparator | Acute oral intake of a placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Salbutamol | Drug | Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximal voluntary activation | Measurement performed by using transcranial magnetic stimulation, superimposed on submaximal and maximal quadricep contractions | Measured immediatly after treatment intake (within 1 h) |
| Measure | Description | Time Frame |
|---|---|---|
| Cortical activation | Measurement performed by using magnetic resonance imaging and the intensity of the BOLD signal in response to a motor task. | Measured immediatly after treatment intake (within 1 h) |
| Exercise endurance |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Michel Guinot, MD PhD | University Hospital, Grenoble | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Grenoble University Hospital | Grenoble | 38042 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000420 | Albuterol |
| ID | Term |
|---|---|
| D004983 | Ethanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Acute oral intake of a placebo drug |
|
|
Time to exhaustion during the exercise muscle test.
| Measured immediatly after treatment intake (within 1 h) |
| D000588 |
| Amines |
| D010627 | Phenethylamines |
| D005021 | Ethylamines |